Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Clinical Neurology
Tammy Jiang, Tjalf Ziemssen, Sibyl Wray, Changyu Shen, Karin Soderbarg, James B. Lewin, Ivan Bozin, Mark S. Freedman
Summary: This study compared the differences between Diroximel fumarate (DRF) and ponesimod (PON) as well as DRF and teriflunomide (TERI) in terms of clinical and radiological outcomes. The study found that there was no strong evidence of differences between DRF and PON in the treatment of relapsing multiple sclerosis, but DRF showed improved efficacy compared to TERI.
Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Dejan Jakimovski, Samreen Awan, Svetlana P. Eckert, Osman Farooq, Bianca Weinstock-Guttman
Summary: POMS is a rare neuroinflammatory and neurodegenerative disease that affects a small percentage of patients before the age of 18. Differential diagnosis is necessary before treatment initiation to exclude other similar acquired demyelinating syndromes. Currently, only two MS DMTs have been approved for pediatric use.
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Aigli G. Vakrakou, Dimitrios Tzanetakos, Eirini Giagkou, Maria-Eleptheria Evangelopoulos, Maria Anagnostouli, Elissavet Andreadou, Georgios Koutsis, Antonios Dimitrakopoulos, Elias Gialafos, John S. Tzartos, Evangelia Kompoti, George E. Fragoulis, Leonidas Stefanis, Constantinos Kilidireas
Summary: This article presents a long-term evaluation of a rare case with both HAE and MS, and examines the impact of current MS treatments on HAE attacks. The study found that fingolimod may have a positive effect on the immunoregulatory mechanisms involved in both diseases.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2022)
Article
Economics
Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna De Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Anneke van der Walt, Vilija G. Jokubaitis, Tomas Kalincik, Helmut Butzkueven
Summary: This study compared the effectiveness and cost-effectiveness of switching to natalizumab or fingolimod for patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies. The results showed that escalating therapy to natalizumab resulted in higher quality-adjusted life-years and lower costs compared to fingolimod for UK patients.
Article
Immunology
Ide Smets, Teresa Prezzemolo, Maya Imbrechts, Klara Mallants, Tania Mitera, Stephanie Humblet-Baron, Benedicte Dubois, Patrick Matthys, Adrian Liston, An Goris
Summary: The study indicates that both fingolimod and interferon-beta induce BAFF protein and mRNA expression, leading to a shift in the B cell pool towards a regulatory phenotype. Specifically, BAFF protein correlated with an increase in transitional B cells, decrease in switched B cells, and reduction in B cell-surface BAFF-R expression. However, BAFF does not directly influence the expression of immunoregulatory cytokines IL-10 and IL-35.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Ophthalmology
Joanna Roskal-Walek, Michal Biskup, Magdalena Dolecka-Slusarczyk, Anita Rosolowska, Andrzej Jaroszynski, Dominik Odrobina
Summary: Susac syndrome (SS) is difficult to diagnose as its clinical triad does not typically occur concurrently, often leading to misdiagnosis as other diseases like multiple sclerosis (MS). Combination therapy with corticosteroids, intravenous immunoglobulins, and azathioprine may improve SS symptoms.
Article
Clinical Neurology
E. J. Ramos Gonzalez, L. J. Ramirez Jirano, D. Z. Garcia Martinez, G. G. Ortiz, L. F. Jave Suarez, C. A. Leal Cortes, O. K. Bitzer Quintero
Summary: The present study compared the effects of MLT administration with IFN-beta and GA in an EAE rat model. Results showed that IFN-beta and GA had better clinical evaluation results compared to MLT. Further research is needed to evaluate the molecular mechanisms of MLT in EAE and quantify other cytokines in different biological media to determine if MLT can be considered as an anti-inflammatory agent for regulating MS.
Article
Immunology
Airi Rump, Kristel Ratas, Tuuli Katarina Lepasepp, Jaanus Suurvali, Olli-Pekka Smolander, Katrin Gross-Paju, Toomas Toomsoo, Jean Kanellopoulos, Sirje Ruutel Boudinot
Summary: Multiple sclerosis (MS) is an inflammatory autoimmune disorder that affects the central nervous system and leads to progressive neurological disability in young adults. It reduces the patient's lifespan by about 10 years and has a higher prevalence in women than men. Early diagnosis and treatment can improve outcomes.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2023)